Taysha Gene Therapies, Inc.
HealthcareNASDAQ:TSHA · NASDAQ Global Select
+$0.13 today
Vol 2.02M · Avg 2.73M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-44.1%
avg -2455.1%
ROIC
-34.9%
avg 65.2%
ROA
-31.7%
avg -1116.4%
Analysis
ROA is currently the strongest return metric at -31.7% versus its period average of -1116.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Sean Nolan | Chief Executive Officer & Chairman | $1.19M | — | 58 | $2.91M | 1.01% |
Sukumar Nagendran | President, Head of Research & Development and Director | $1.04M | — | 59 | $1.14M | 0.40% |
Kamran Alam | Chief Financial Officer & Corporate Secretary | $741,904.00 | — | 48 | $1.44M | 0.50% |
Berge Minassian | Chief Medical Advisor of UT Southwestern Gene Therapy Program | — | — | — | — | — |
Hayleigh Collins | Director of Corporate Communications & Investor Relations | — | — | — | — | — |
David McNinch | Chief Commercial Officer | — | — | 57 | — | — |
Frederick Porter | Chief of Staff & Technical Operations Officer | — | — | — | — | — |
Sean McAuliffe | Chief Business Officer | — | — | — | $2.91M | 1.01% |
Emily McGinnis | Chief Patient & External Affairs Officer | — | — | — | — | — |
Rumana Haque-Ahmed | Chief Regulatory Officer | — | — | — | — | — |
Steven Gray | Chief Scientific Advisor of UT Southwestern Gene Therapy Program | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
14
$6.37M
Net Sentiment
$6.37M
Net selling
Most Active
Nagendran Sukumar
8 transactions
1–10 of 14
Analysis
Insiders reported 0 buys worth $0.00 and 14 sells worth $6.37M over the last 12 months. That adds up to net selling of $6.37M. Nagendran Sukumar was the most active insider with 8 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | +80.3% (7yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Forward estimates point to Revenue at +80.3% (7yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
$3.43B
Enliven Therapeutics, Inc.
NASDAQ:ELVN
$2.81B
AnaptysBio, Inc.
NASDAQ:ANAB
$2.42B
Atai Beckley Inc.
NASDAQ:ATAI
$1.44B
Immatics N.V.
NASDAQ:IMTX
$1.26B
Nektar Therapeutics
NASDAQ:NKTR
$1.16B
Xencor, Inc.
NASDAQ:XNCR
$914.17M
Sana Biotechnology, Inc.
NASDAQ:SANA
$745.82M
Oculis Holding AG
NASDAQ:OCS
$634.01M
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
$620.83M
Who manages TSHA?
Taysha Gene Therapies, Inc. (TSHA) lists 11 active executives. The top listed executive is Berge Minassian, Chief Medical Advisor of UT Southwestern Gene Therapy Program.
Are TSHA insiders buying or selling?
Recent insider activity shows net buying of $54.40M.
Explore More
Continue the stock analysis
Jump to another research area for this company.